Edition:
United States

Celgene Corp (CELG.O)

CELG.O on Nasdaq

115.71USD
22 May 2017
Change (% chg)

$-1.22 (-1.04%)
Prev Close
$116.93
Open
$116.50
Day's High
$116.69
Day's Low
$113.63
Volume
5,685,232
Avg. Vol
3,783,658
52-wk High
$127.64
52-wk Low
$94.42

CELG.O

Chart for CELG.O

About

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology... (more)

Overall

Beta: 1.84
Market Cap(Mil.): $91,301.79
Shares Outstanding(Mil.): 780.82
Dividend: --
Yield (%): --

Financials

  CELG.O Industry Sector
P/E (TTM): 44.04 142.93 17.37
EPS (TTM): 2.65 -- --
ROI: 8.50 2.34 -5.89
ROE: 33.64 0.22 -5.30

Celgene MS drug clears key trial, but disability data falls short

Celgene Corp's multiple sclerosis drug met the main goal of reducing annualized relapse rate, compared with Biogen Inc's Avonex, in a second late-stage trial, but failed to outperform Avonex in slowing disability progression rate.

12:24pm EDT

UPDATE 2-Celgene MS drug clears key trial, but disability data falls short

May 22 Celgene Corp's multiple sclerosis drug met the main goal of reducing annualized relapse rate, compared with Biogen Inc's Avonex, in a second late-stage trial, but failed to outperform Avonex in slowing disability progression rate.

12:22pm EDT

Celgene's multiple sclerosis drug succeeds in late-stage trial

May 22 Celgene Corp said its oral drug to treat relapsing multiple sclerosis met the main goal of reducing annualized relapse rate, when compared to Biogen Inc's Avonex, in a second late-stage study.

7:54am EDT

BRIEF-Celgene announces positive results from radiance

* Celgene announces positive results from radiance, the second pivotal phase III trial of oral ozanimod in patients with relapsing multiple sclerosis

7:42am EDT

Celgene leukemia drug extends survival in early stage trial

Nearly 20 percent of patients with an aggressive form of leukemia experienced complete remission along with prolonged survival from treatment with an experimental Celgene Corp drug, according to data from an early-stage study released on Wednesday.

May 17 2017

Celgene leukemia drug extends survival in early stage trial

May 17 Nearly 20 percent of patients with an aggressive form of leukemia experienced complete remission along with prolonged survival from treatment with an experimental Celgene Corp drug, according to data from an early-stage study released on Wednesday.

May 17 2017

Celgene 1st quarter sales miss; expects psoriasis drug rebound

Celgene Corp on Thursday reported lower-than-expected first-quarter revenue with Otezla sales well short of Wall Street estimates, but the U.S. biotechnology company promised the psoriasis drug was poised to rebound.

Apr 27 2017

UPDATE 3-Celgene 1st quarter sales miss; expects psoriasis drug rebound

April 27 Celgene Corp on Thursday reported lower-than-expected first-quarter revenue with Otezla sales well short of Wall Street estimates, but the U.S. biotechnology company promised the psoriasis drug was poised to rebound.

Apr 27 2017

BRIEF-Celgene on track to achieve or exceed 2020 forecast - CEO

* Celgene CEO says on track to achieve or exceed 2020 forecast

Apr 27 2017

RPT-UPDATE 1-Celgene quarterly profit beats on Revlimid demand

April 27 U.S. biotechnology company Celgene Corp reported a better-than-expected profit on Thursday, helped by demand for its flagship multiple myeloma drug Revlimid.

Apr 27 2017

More From Around the Web

Competitors

Earnings vs. Estimates